Alerts will be sent to your verified email
Verify Email
JAGSNPHARM
|
Jagsonpal Pharma
|
Syncom Formulations
|
Beta Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
16.01 % | 9.79 % | 21.73 % |
|
5yr average Equity Multiplier
|
1.27 | 1.41 | 1.75 |
|
5yr Average Asset Turnover Ratio
|
1.09 | 0.81 | 1.04 |
|
5yr Avg Net Profit Margin
|
12.08 % | 8.78 % | 11.97 % |
|
Price to Book
|
5.53 | 4.0 | 0.0 |
|
P/E
|
22.58 | 24.0 | 39.43 |
|
5yr Avg Cash Conversion Cycle
|
2.39 Days | 61.57 Days | 15.7 Days |
|
Inventory Days
|
37.29 Days | 27.32 Days | 43.83 Days |
|
Days Receivable
|
15.63 Days | 82.75 Days | 87.61 Days |
|
Days Payable
|
59.94 Days | 79.41 Days | 113.94 Days |
|
5yr Average Interest Coverage Ratio
|
66.99 | 31.44 | 13.71 |
|
5yr Avg ROCE
|
18.99 % | 13.63 % | 27.85 % |
|
5yr Avg Operating Profit Margin
|
13.23 % | 9.97 % | 21.58 % |
|
5 yr average Debt to Equity
|
0.01 | 0.19 | 0.23 |
|
5yr CAGR Net Profit
|
26.54 % | 36.24 % | 31.07 % |
|
5yr Average Return on Assets
|
12.71 % | 7.11 % | 12.53 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
67.54 % | 50.57 % | 66.73 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-1.18 % | 0.0 | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Jagsonpal Pharma
|
Syncom Formulations
|
Beta Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|